Fortress Biotech (FBIO) Capital Expenditures (2010 - 2024)
Fortress Biotech (FBIO) posted quarterly Capital Expenditures of -$1.4 million for Q3 2024, down 139600.0% year-over-year from N/an in Q4 2023, and down 200.0% quarter-over-quarter from $1.4 million in Q2 2024.
Powered by 
Analysis
Fortress Biotech (FBIO) Capital Expenditures (2010 - 2024) Analysis & Trends
Fortress Biotech's Capital Expenditures history runs 12 years deep, the most recent figure standing at -$1.4 million for Q3 2024.
- In Q3 2024, Capital Expenditures fell 139600.0% year-over-year to -$1.4 million; the TTM figure through Sep 2024 stood at $28000.0 (down 98.97% YoY), while the FY2023 annual figure was $63000.0, down 97.68% from the prior year.
- Capital Expenditures for Q3 2024 stood at -$1.4 million, down from $1.4 million in the prior quarter.
- The five-year high for Capital Expenditures was $2.7 million in Q4 2022, with the low at -$1.6 million in Q3 2022.
- The 5-year median for Capital Expenditures is $384000.0 (2021), against an average of $515000.0.
- Peak annual rise in Capital Expenditures reached 8618.75% in 2024, while the deepest fall reached 139600.0% in 2024.
- Fortress Biotech's Capital Expenditures stood at $1.6 million in 2020, then increased by 21.63% to $2.0 million in 2021, then surged by 37.66% to $2.7 million in 2022, then plunged by 98.96% to $28000.0 in 2023, then slumped by 5082.14% to -$1.4 million in 2024.
- Business Quant data shows FBIO's Capital Expenditures at -$1.4 million in Q3 2024, $1.4 million in Q2 2024, and $28000.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Fortress Biotech | 86.15 Mn | -110.42 Mn | 12.58 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | -1.40 Mn |
| Jun 30, 2024 | 1.40 Mn |
| Dec 31, 2023 | 28,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 16,000.00 |
| Mar 31, 2023 | 18,000.00 |
| Dec 31, 2022 | 91,000.00 |
| Sep 30, 2022 | 980,000.00 |
| Jun 30, 2022 | 307,000.00 |
| Mar 31, 2022 | 1.34 Mn |
| Dec 31, 2021 | 1.96 Mn |
| Sep 30, 2021 | 461,000.00 |
| Jun 30, 2021 | 1.60 Mn |
| Mar 31, 2021 | 545,000.00 |
| Dec 31, 2020 | 698,000.00 |
| Sep 30, 2020 | -521,000.00 |
| Jun 30, 2020 | 1.21 Mn |
| Mar 31, 2020 | 540,000.00 |
| Dec 31, 2019 | 890,000.00 |
| Sep 30, 2019 | 500,000.00 |